<DOC>
	<DOCNO>NCT00002354</DOCNO>
	<brief_summary>The purpose study see safe effective give indinavir sulfate plus stavudine HIV-infected patient already treat zidovudine .</brief_summary>
	<brief_title>A Study Indinavir Sulfate Given Together With Stavudine HIV-Positive Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Prophylaxis aerosolize pentamidine , topical antifungal , TMP / SMX , dapsone , isoniazid . Patients must : HIV infection . CD4 count 50 500 cells/mm3 . Prior AZT use 6 month OR document intolerance AZT 6 month use another antiHIV therapy d4T protease inhibitor . No active opportunistic infection visceral Kaposi 's sarcoma . NOTE : Patients hemophilia may enrol discretion investigator . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Symptomatic neuropathy . Acute hepatitis . Concurrent Medication : Excluded : Antiretrovirals specify protocol . Chronic therapy active opportunistic infection . Immunosuppressive therapy . Prior Medication : Excluded : Any prior protease inhibitor d4T . Any nucleoside analog within 2 week prior study entry . Investigational agent immunomodulators within 30 day prior study entry . Required : More 6 month prior AZT unless intolerant , case 6 month another antiHIV therapy ( protease inhibitor d4T ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 1996</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Stavudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Indinavir</keyword>
</DOC>